Developing faster and more accurate diagnosis of sepsis
Sepsis is a life-threatening condition that occurs when the body's response to an infection damages its own tissues. Early recognition and treatment can improve the chance of survival.
The Optimising Treatment Outcomes for Children and Adults Through Rapid Genome Sequencing of Sepsis Pathogens (DIRECT) study set out to describe the feasibility of an integrated diagnostic and therapeutic intervention, using whole genome sequencing and antibiotic dosing software, to reduce the time to effective antibiotic exposure in critically ill children and adults with sepsis.
Through the DIRECT study, the project team has demonstrated the feasibility of metagenomic sequencing of pathogens from positive blood cultures and of the impact of antibiotic dosing software in a multi-centre trial in ICUs. The results of the trial highlight the potential for these diagnostic and therapeutic innovations in the management of critically ill children and adults with sepsis.
The project team included expertise from partners within universities, research institutes, and hospital and health services around Queensland.
This project was supported by funding from the Australian Government under the Medical Research Future Fund’s RART 2.1 and RART 2.2 grant schemes. These results relate to research work completed under both grants (2.1 and 2.2).
Health Translation Queensland acknowledges the Traditional Owners and their custodianship of the lands on which we live, work, and play. We pay our respects to their Ancestors and their Descendants, who continue cultural and spiritual connections to Country. We recognise their valuable contributions to Australian and global society.